ELUT
Elutia Inc - Class A (ELUT)
Healthcare • NASDAQ • $1.01+1.12%
- Symbol
- ELUT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $1.01
- Daily Change
- +1.12%
- Market Cap
- $47.03M
- Trailing P/E
- N/A
- Forward P/E
- -0.92
- 52W High
- $2.64
- 52W Low
- $0.50
- Analyst Target
- $5.00
- Dividend Yield
- N/A
- Beta
- 0.76
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable …
Company websiteResearch ELUT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.